<?xml version="1.0" encoding="UTF-8"?>
<ref id="B28-vaccines-07-00074">
 <label>28.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Euler</surname>
    <given-names>Z.</given-names>
   </name>
   <name>
    <surname>van den Kerkhof</surname>
    <given-names>T.L.G.M.</given-names>
   </name>
   <name>
    <surname>van Gils</surname>
    <given-names>M.J.</given-names>
   </name>
   <name>
    <surname>Burger</surname>
    <given-names>J.A.</given-names>
   </name>
   <name>
    <surname>Edo-Matas</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Phung</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Wrin</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>Schuitemaker</surname>
    <given-names>H.</given-names>
   </name>
  </person-group>
  <article-title>Longitudinal analysis of early HIV-1-specific neutralizing activity in an elite neutralizer and in five patients who developed cross-reactive neutralizing activity</article-title>
  <source>J. Virol.</source>
  <year>2012</year>
  <volume>86</volume>
  <fpage>2045</fpage>
  <lpage>2055</lpage>
  <pub-id pub-id-type="doi">10.1128/JVI.06091-11</pub-id>
  <pub-id pub-id-type="pmid">22156522</pub-id>
 </element-citation>
</ref>
